CA2896568C - TREATMENT OF THALAMOCORTICAL DYSRYTHMIA - Google Patents

TREATMENT OF THALAMOCORTICAL DYSRYTHMIA

Info

Publication number
CA2896568C
CA2896568C CA2896568A CA2896568A CA2896568C CA 2896568 C CA2896568 C CA 2896568C CA 2896568 A CA2896568 A CA 2896568A CA 2896568 A CA2896568 A CA 2896568A CA 2896568 C CA2896568 C CA 2896568C
Authority
CA
Canada
Prior art keywords
therapy
tlves
tms
patient
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2896568A
Other languages
English (en)
French (fr)
Other versions
CA2896568A1 (en
Inventor
Steven Richard Devore Best
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2896568A1 publication Critical patent/CA2896568A1/en
Application granted granted Critical
Publication of CA2896568C publication Critical patent/CA2896568C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00Magnetotherapy
    • A61N2/002Magnetotherapy in combination with another treatment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M19/00Local anaesthesia; Hypothermia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36014External stimulators, e.g. with patch electrodes
    • A61N1/36021External stimulators, e.g. with patch electrodes for treatment of pain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36014External stimulators, e.g. with patch electrodes
    • A61N1/36025External stimulators, e.g. with patch electrodes for treating a mental or cerebral condition
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00Magnetotherapy
    • A61N2/004Magnetotherapy specially adapted for a specific therapy
    • A61N2/006Magnetotherapy specially adapted for a specific therapy for magnetic stimulation of nerve tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00Magnetotherapy
    • A61N2/004Magnetotherapy specially adapted for a specific therapy
    • A61N2/008Magnetotherapy specially adapted for a specific therapy for pain treatment or analgesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00Magnetotherapy
    • A61N2/02Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M21/00Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
    • A61M2021/0005Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus
    • A61M2021/0055Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus with electric or electro-magnetic fields
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M21/00Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00Special media to be introduced, removed or treated
    • A61M2202/04Liquids
    • A61M2202/0468Liquids non-physiological
    • A61M2202/048Anaesthetics
    • FMECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F04POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
    • F04CROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT MACHINES FOR LIQUIDS; ROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT PUMPS
    • F04C2270/00Control; Monitoring or safety arrangements
    • F04C2270/04Force
    • F04C2270/042Force radial
    • F04C2270/0421Controlled or regulated

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Radiology & Medical Imaging (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Developmental Disabilities (AREA)
  • Social Psychology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Acoustics & Sound (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Magnetic Treatment Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2896568A 2012-11-25 2013-11-21 TREATMENT OF THALAMOCORTICAL DYSRYTHMIA Active CA2896568C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261729625P 2012-11-25 2012-11-25
US61/729,625 2012-11-25
US13/826,250 US8974365B2 (en) 2012-11-25 2013-03-14 Treatment of thalamocortical dysrhythmia
US13/826,250 2013-03-14
PCT/US2013/071275 WO2014081948A1 (en) 2012-11-25 2013-11-21 Treatment of thalamocortical dysrhythmia

Publications (2)

Publication Number Publication Date
CA2896568A1 CA2896568A1 (en) 2014-05-30
CA2896568C true CA2896568C (en) 2025-06-17

Family

ID=50773848

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2896568A Active CA2896568C (en) 2012-11-25 2013-11-21 TREATMENT OF THALAMOCORTICAL DYSRYTHMIA

Country Status (10)

Country Link
US (5) US8974365B2 (enExample)
EP (2) EP2922591B1 (enExample)
JP (5) JP2016501865A (enExample)
KR (5) KR20200117062A (enExample)
CN (1) CN104981265A (enExample)
CA (1) CA2896568C (enExample)
ES (1) ES2882619T3 (enExample)
IL (2) IL273912B2 (enExample)
MX (1) MX2015006444A (enExample)
WO (1) WO2014081948A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10155114B2 (en) * 2014-06-03 2018-12-18 Dirk De Ridder Systems and methods of treating a neurological disorder in a patient
US10118038B2 (en) * 2015-03-24 2018-11-06 Dirk De Ridder Methods of neuromodulation
US10201708B2 (en) 2014-10-29 2019-02-12 Dirk De Ridder Method of treating a neurological disorder using network stimulation
EP3416723A4 (en) * 2016-02-21 2019-07-17 Tech Innosphere Engineering Ltd. NONINVASIVE ELECTRICAL BRAIN STIMULATION SYSTEM
US10596378B2 (en) * 2016-10-18 2020-03-24 Joseph Rustick Method for treatment of depression using synaptic pathway training
US9950189B1 (en) * 2016-10-20 2018-04-24 Neuro-Laser Foundation Inc. Treatment methodologies using light therapy
US10905897B2 (en) * 2016-10-20 2021-02-02 Neuro-Laser Foundation, Inc. Synergistic treatment methodologies using light therapy
US11723579B2 (en) 2017-09-19 2023-08-15 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement
MY197404A (en) * 2017-11-22 2023-06-16 Lin Chieh Hsin Benzoic acid or a salt and derivative thereof for use in preventing or treating depression
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
KR102099200B1 (ko) * 2017-12-18 2020-04-09 서울대학교산학협력단 뇌 자극 장치
EP3505157B1 (en) 2017-12-29 2021-12-08 Celon Pharma S.A. Dry powder ketamine composition for pulmonary administration in treatment-resistant depression
US11478603B2 (en) 2017-12-31 2022-10-25 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US12280219B2 (en) 2017-12-31 2025-04-22 NeuroLight, Inc. Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
WO2020056418A1 (en) 2018-09-14 2020-03-19 Neuroenhancement Lab, LLC System and method of improving sleep
CN109481845B (zh) * 2018-12-28 2022-04-01 深圳先进技术研究院 一种作用于不同脑区的经颅磁刺激的方法和相关装置
CN110064117B (zh) * 2019-03-27 2021-06-01 佛山职业技术学院 一种基于呐喊声音的心理宣泄交互方法及装置
EP3951075B1 (en) 2019-03-28 2024-07-24 Sumitomo Construction Machinery Co., Ltd. Shovel and construction system
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
US12059565B1 (en) * 2019-12-19 2024-08-13 Washington University Methods and systems for modulating unconsciousness or anesthesia in a subject
CN113041501A (zh) * 2021-03-22 2021-06-29 东南大学 联合磁刺激系统靶向视觉皮层快速抗抑郁的方法
WO2022235576A1 (en) * 2021-05-03 2022-11-10 Wang Michael Z Methods and compositions for treating depression
ES2994763B2 (es) * 2023-07-25 2025-11-03 Nauta Technomedical Res S L Sistema de neuroestimulacion magnetica hiperbarica con ajuste parametrico semi automatico personalizable

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084007A (en) * 1989-08-11 1992-01-28 Malin David H Method for chemical promotion of the effects of low current transcranial electrostimulation
US6132361A (en) * 1994-11-28 2000-10-17 Neotonus, Inc. Transcranial brain stimulation
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
US6176242B1 (en) * 1999-04-30 2001-01-23 Medtronic Inc Method of treating manic depression by brain infusion
US6591138B1 (en) * 2000-08-31 2003-07-08 Neuropace, Inc. Low frequency neurostimulator for the treatment of neurological disorders
US20110307029A1 (en) * 2008-08-06 2011-12-15 Cerephex Corporation Brain stimulation methods for treating central sensitivity
US7687080B2 (en) * 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
US8052591B2 (en) * 2006-05-05 2011-11-08 The Board Of Trustees Of The Leland Stanford Junior University Trajectory-based deep-brain stereotactic transcranial magnetic stimulation
CA2580694A1 (en) 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US7613520B2 (en) * 2004-10-21 2009-11-03 Advanced Neuromodulation Systems, Inc. Spinal cord stimulation to treat auditory dysfunction
CN101686945A (zh) * 2004-11-23 2010-03-31 埃德莫斯药品有限公司 包含持续释放的包衣或基质和nmda受体拮抗剂的组合物,以及向受治疗者施用该nmda受体拮抗剂的方法
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US8676330B2 (en) * 2009-03-20 2014-03-18 ElectroCore, LLC Electrical and magnetic stimulators used to treat migraine/sinus headache and comorbid disorders
CN101432011A (zh) * 2006-02-27 2009-05-13 亚历山大·米哈洛 通过诱导逆适应调节神经递质系统的方法
US20100113959A1 (en) * 2006-03-07 2010-05-06 Beth Israel Deaconess Medical Center, Inc. Transcranial magnetic stimulation (tms) methods and apparatus
JP2009530385A (ja) * 2006-03-22 2009-08-27 マウント シナイ スクール オブ メディシン うつ病の治療のためのケタミンの鼻内投与
US7949403B2 (en) * 2007-02-27 2011-05-24 Accelerated Care Plus Corp. Electrical stimulation device and method for the treatment of neurological disorders
CA2722776A1 (en) * 2008-05-09 2009-11-12 Emory University Nmda receptor antagonists for the treatment of neuropsychiatric disorders
WO2010009141A1 (en) * 2008-07-14 2010-01-21 Arizona Board Of Regents For And On Behalf Of Arizona State University Methods and devices for modulating cellular activity using ultrasound
WO2010017249A1 (en) * 2008-08-04 2010-02-11 The Trustees Of Columbia University In The City Of New York Methods, apparatus and systems for magnetics stimulation
US8674095B2 (en) 2008-12-19 2014-03-18 Afraxis Holdings, Inc. Compounds for treating neuropsychiatric conditions
ES2672987T3 (es) * 2009-03-02 2018-06-19 Yeda Research And Development Co. Ltd. Esquema de configuración magnética y sincronización para la estimulación magnética transcraneal
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
CA2776770A1 (en) * 2009-10-09 2011-04-14 Afraxis, Inc. 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
KR20120107993A (ko) * 2009-12-15 2012-10-04 뉴롭, 인코포레이티드 신경계 장애의 치료를 위한 화합물
WO2011123548A2 (en) * 2010-04-02 2011-10-06 Neostim, Inc Neuromodulation of deep-brain targets by transcranial magnetic stimulation enhanced by transcranial direct current stimulation
US20140058189A1 (en) * 2012-02-20 2014-02-27 William F. Stubbeman Systems and methods using brain stimulation for treating disorders

Also Published As

Publication number Publication date
EP3915551A1 (en) 2021-12-01
CN104981265A (zh) 2015-10-14
KR20230141875A (ko) 2023-10-10
IL238979B (en) 2020-08-31
US20150165224A1 (en) 2015-06-18
US20210101015A1 (en) 2021-04-08
JP2019065021A (ja) 2019-04-25
IL273912B2 (en) 2024-11-01
KR20250046361A (ko) 2025-04-02
MX2015006444A (es) 2015-10-29
KR20200117062A (ko) 2020-10-13
IL273912B1 (en) 2024-07-01
JP2020180141A (ja) 2020-11-05
US20140148636A1 (en) 2014-05-29
KR20220132667A (ko) 2022-09-30
HK1215687A1 (zh) 2016-09-09
CA2896568A1 (en) 2014-05-30
US8974365B2 (en) 2015-03-10
ES2882619T3 (es) 2021-12-02
EP2922591A1 (en) 2015-09-30
IL273912A (en) 2020-05-31
US20180001104A1 (en) 2018-01-04
US9649501B2 (en) 2017-05-16
EP2922591A4 (en) 2016-08-10
JP2025029043A (ja) 2025-03-05
JP2016501865A (ja) 2016-01-21
US10716950B2 (en) 2020-07-21
WO2014081948A1 (en) 2014-05-30
US20240207630A1 (en) 2024-06-27
KR20150091323A (ko) 2015-08-10
IL238979A0 (en) 2015-07-30
JP2022188221A (ja) 2022-12-20
EP2922591B1 (en) 2021-05-12

Similar Documents

Publication Publication Date Title
CA2896568C (en) TREATMENT OF THALAMOCORTICAL DYSRYTHMIA
MX2016005159A (es) Metodos de diagnostico y tratamiento de trastornos eosinofilicos.
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
NZ700759A (en) Combination therapy for treating cancer
NZ630367A (en) Methods of treatment of pediatric solid tumor
GB201016812D0 (en) Method and apparatus for treating respiratory diesease
EP4252833A3 (en) Microstimulation sleep disordered breathing (sdb) therapy device
GB201105622D0 (en) Multi functional catheter
WO2014151431A3 (en) Method and apparatus for transdermal stimulation over the palmar and plantar surfaces
MX2010012860A (es) Metodos para tratar cancer del sistema nervioso central.
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
GB2514504A (en) Apparatus and method for irradiating biological tissue
SG10201810575WA (en) Treatment of prostate cancer with tor kinase inhibitors
MX2016005614A (es) Cuerpos de inclusion para el suministro transdermico de agentes terapeuticos y cosmeticos.
MX358512B (es) Uso de (r)-7cloro-n-(quinuclidin-3-il) benzo[b] tiofeno-2-carboxamida o una sal farmacéuticamente aceptable de la misma para preparar una composición farmacéutica en el tratamiento de una disfunción cognitiva.
RU2010130331A (ru) Способ лечения неврозов
UA82042U (ru) Способ лечения цефалгического синдрома у больных с последствиями перенесенных послегриппозных нейроинфекций
NZ628130A (en) Treatment of addiction and impulse-control disorders using pde7 inhibitors
UA77025U (ru) Способ лечения больных с черепно-мозговой травмой
RU2010116789A (ru) Способ лечения травматических невропатий
UA74810U (ru) Способ воздействия на организм магнитным полем
UA79983U (en) method for treating patients with vertebral-spinal injury
UA78085U (uk) Спосіб лікування хворих з травматичним ураженням шийного відділу спинного мозку при хребетно-спинномозковій травмі
UA57780U (ru) Способ лечения онкологических заболеваний
UA78211U (ru) Способ лечения больных с позвоночно-спинномозговой травмой грудного отдела

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20171106

EEER Examination request

Effective date: 20171106

EEER Examination request

Effective date: 20171106

EEER Examination request

Effective date: 20171106

EEER Examination request

Effective date: 20171106

EEER Examination request

Effective date: 20171106

EEER Examination request

Effective date: 20171106

EEER Examination request

Effective date: 20171106